BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates

Stock News

09/16

BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as "Baiyunshan Pharmaceutical General Factory"), has recently received "Drug Supplementary Application Approval Notifications" issued by the National Medical Products Administration.

According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.

The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1106459077"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106459077\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106459077?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106459077","market":"fut","top_or_hot":-1,"title":"BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates","media":"Stock News","content":"<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.</p>\n<p>The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAIYUNSHAN PH (00874) Subsidiary Receives Drug Supplementary Application Approval Certificates\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-16 17:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.</p>\n<p>According to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.</p>\n<p>The company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0097","symbol_name":"醫藥電商","start_time":0,"source_url":"","article_id":"1106459077","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106459077","pubTimestamp":1758014063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0097":"医药电商","BK0239":"医药制造","BK1197":"保健护理产品经销商","01477":"欧康维视生物-B","BK0096":"民营医院","BK1521":"挪威政府全球养老基金持仓","BK0183":"MSCI概念","00874":"白云山","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","BK1191":"制药","BK0175":"白马股","BK1606":"中医药概念","BK0070":"员工持股","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK0196":"行业龙头"},"translate_title":"白云山PH(00874)子公司获药品补充申请批准证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":1,"00874":1,"01477":1},"content_text":"BAIYUNSHAN PH (00874) announced that its subsidiary, Guangzhou Baiyunshan Medical Group Co., Ltd. Baiyunshan Pharmaceutical General Factory (referred to as \"Baiyunshan Pharmaceutical General Factory\"), has recently received \"Drug Supplementary Application Approval Notifications\" issued by the National Medical Products Administration.\nAccording to the announcement, Baiyunshan Pharmaceutical General Factory obtained Drug Supplementary Application Approval Notifications for Fukean tablets, Kunling pills, Shenxi Dan, Yiganning tablets, and Maian granules. The approvals enhance safety and other information for these pharmaceutical products, contributing to their safe, effective, and rational use, while helping to improve the products' market competitiveness.\nThe company noted that receiving these Drug Supplementary Application Approval Notifications will not have a significant impact on its current financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}